Tactile Systems Technology, Inc. — Cyborg Score 7/10
Solid
Medical Devices - Therapeutic Compression & Airway Clearance
Strategic Profile
The company offers multiple proprietary devices including Flexitouch Plus for lymphedema treatment, Entre Plus System for compression therapy, Nimbl for upper extremity treatment, and AffloVest for airway clearance. Recently, Tactile acquired LymphaTech Inc. in February 2026 for $6.8 million upfront, adding a 3D measurement platform designed specifically for lymphedema management, strengthening its market position through strategic portfolio expansion.
Cyborg Score Rationale
The company projects 2026 revenue growth of 8-11%, though this accounts for headwinds from new Medicare prior authorization requirements for pneumatic compression devices. A robust cash position of $83.4 million supports continued investment and acquisition strategy, though regulatory headwinds present near-term execution risk.
Top Insights
February 2026 acquisition of LymphaTech adds digital 3D measurement technology to expand lymphedema detection and monitoring capabilities